Materialise Q2 Earnings Call Highlights

Materialise logo

MarketBeat

Thu, August 27, 2026 at 5:04 PM GMT+3 6 min read

Key Points

Interested in Materialise NV? Here are five stocks we like better.
Materialise raised its full-year adjusted EBIT outlook to €12 million–€14 million from €10 million–€12 million, while maintaining revenue guidance of €273 million–€283 million. Second-quarter revenue rose more than 8% to €70.1 million, with adjusted EBITDA up nearly 16% to €9.6 million.
Medical led growth, with revenue increasing more than 12% and medical-device revenue up 19%, although medical software declined 4% amid weaker research grants and cautious customer spending. Manufacturing revenue rose nearly 7%, helped by 40% aerospace growth, while its adjusted EBITDA loss narrowed substantially.
Materialise is focusing on scalable businesses by completing the divestitures of RapidFit and Eyewear and advancing its subscription-based software portfolio. Software revenue fell 3%, but recurring revenue reached 86% as new CO-AM products target longer-term growth in aerospace, defense and other industrial markets.

Materialise NVStock Bottom is Materializing

Materialise (NASDAQ:MTLS) reported second-quarter revenue growth of more than 8% year over year to €70.1 million, driven by double-digit expansion in its Medical segment and continued improvement in profitability. The company raised its full-year adjusted EBIT outlook while maintaining its revenue guidance, despite the anticipated revenue effect of divesting its RapidFit and Eyewear businesses.

Chief Executive Officer Brigitte de Vet said the company's first-half performance supported its confidence in its 2026 plan. Materialise now expects full-year adjusted EBIT of €12 million to €14 million, up from its prior forecast of €10 million to €12 million. It reaffirmed revenue guidance of €273 million to €283 million.

Second-Quarter Financial Results

→ NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing?

Second-quarter gross profit rose to €39.8 million, producing a gross margin of 56.8%. Adjusted EBITDA increased nearly 16% from a year earlier to €9.6 million, or 13.7% of revenue. Adjusted EBIT reached €3.9 million, compared with €3.1 million in the prior-year quarter, and the adjusted EBIT margin expanded to 5.5%.

Net profit totaled €3.3 million, or €0.06 per share. For the first half, net profit was €5.1 million, or €0.09 per share, while revenue increased nearly 4% to €136.3 million. First-half adjusted EBITDA was €17.6 million and adjusted EBIT was €6.4 million.

→ Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding

Chief Financial Officer Koen Berges attributed the margin improvement to revenue growth, cost management, operational efficiencies and a sharper focus on core growth segments. Operating expenses increased 3.9% in the quarter, while research-and-development spending exceeded €12 million, up 11% year over year. Materialise said it continued to make targeted investments in new products and growth opportunities.

The company ended the quarter with €133.7 million in cash and €59.5 million in gross debt, resulting in net cash of €74.2 million, up €3.4 million from the beginning of the year. It spent €5.2 million during the first six months on share repurchases, acquiring nearly 1.1 million American depositary shares, or 1.8% of its share base as of June 30.

Medical Leads Growth as Software Revenue Declines

→ DICK's Sporting Goods Faces Pain Now for a Bigger Prize

Medical revenue increased more than 12% in the second quarter, with medical-device revenue up 19% across partner and direct-sales channels. Medical software revenue declined 4%. The Medical segment generated adjusted EBITDA of €11.6 million, representing a 31% margin.

De Vet told analysts that Medical's sustainable structural growth rate should be in the low-double digits, or around 10%, though quarterly results can vary because of timing effects. She said softer medical-software revenue partly reflected reduced research grants at U.S. academic centers, which use Materialise software for training and research but do not typically purchase its device and service offerings.

She also cited differing reimbursement conditions across the markets served by the company. Materialise's software portfolio has historically been more concentrated in orthopedics, where reimbursement changes in the U.S. have contributed to more cautious customer spending, she said.

During the quarter, Materialise announced an investment in Belgian medtech startup Replasia, which develops personalized 3D-printed solutions and anatomical-analysis software for hip preservation. De Vet said the investment complements Materialise's hip-replacement portfolio and broadens its position in personalized hip care as the market moves toward less invasive treatments.

Software Transition and Manufacturing Portfolio Changes

Software revenue declined 3% to €9.6 million in the second quarter, as customers remained cautious and sales cycles lengthened in the industrial market. However, 86% of software revenue was recurring as the company neared the completion of its transition from perpetual licenses to a subscription model.

Materialise released CO-AM Pro on May 15, one month ahead of schedule. The cloud-based offering is integrated with Magics and combines additive-manufacturing data management with build preparation. The company also formally released its CO-AM Bricks automation platform and began early-adopter programs for CO-AM NPI and CO-AM Enterprise.

De Vet said the NPI and Enterprise offerings are expected to be longer-term software growth drivers because they target companies seeking to scale established additive-manufacturing operations, particularly in aerospace and defense. Software adjusted EBITDA declined to €1 million during the quarter as lower revenue and investment in new functionality weighed on results.

Manufacturing revenue rose nearly 7% to €23.6 million despite the impact of the RapidFit divestment. Aerospace revenue grew 40%, while continued weak prototyping demand partly offset growth in series manufacturing. The segment's adjusted EBITDA loss narrowed to €0.3 million from a €4.8 million loss a year earlier.

Materialise completed the transfer of RapidFit to its management team on April 30 and closed the transfer of its Eyewear business on July 1. The company retained a 20% minority stake in Eyewear. Berges said the transactions are intended to focus capital and management resources on business lines with stronger long-term scaling potential.

Leadership Changes and Outlook

Materialise also announced executive committee changes effective in early September. Annelies Smits-Ottens will join as chief human resource officer, and Philippe Verlinden will assume the newly created role of chief digital and information officer. The company is also seeking a new leader for its Medical segment, with current Medical leader Koen Peters set to leave in September.

On the earnings outlook, Berges said Materialise expects typical seasonal patterns to persist, with the third quarter generally softer and the fourth quarter usually stronger. He said extrapolating first-half EBIT would place the company near the middle of its updated full-year guidance range.

About Materialise (NASDAQ:MTLS)

Materialise NV is a Belgium-based company specializing in 3D printing software and additive manufacturing services. Through its dual focus on software and printing, the company addresses a wide range of industries, including automotive, aerospace, consumer goods, and healthcare. Materialise's offerings span from design and simulation tools to end-to-end production, delivering both standardized and highly customized parts across polymer and metal platforms.

On the software side, Materialise develops a suite of proprietary applications—such as Magics for data preparation, Mimics for medical image processing and patient-specific modeling, and Streamics for production workflow management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

The article "Materialise Q2 Earnings Call Highlights" was originally published by MarketBeat.

View MarketBeat's top stocks for August 2026.